

Molecular Diagnostics For STD Market Size, Share and Growth Outlook 2026: By Product (Consumables (Reagents and Kits), Instruments and Services, Software), By Application, By Location of Testing, Companies to 2034.

<https://marketpublishers.com/r/M6993DAD57C5EN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,482.00 (Single User License)

ID: M6993DAD57C5EN

Abstracts

The global Molecular Diagnostics For STD Market size is forecast to increase from \$4.56 Billion in 2026 to \$8.86 Billion in 2034 at a CAGR of 8.66% between 2026 and 2034.

The Molecular Diagnostics For STD market report provides detailed analysis and outlook of Molecular Diagnostics For STD segments including By Product (Consumables (Reagents and Kits), Instruments and Services, Software), By Application (Chlamydia Trachomatis / Neisseria Gonorrhoeae (CT/NG) Testing, Human Immunodeficiency Virus (HIV) Testing, Human Papillomavirus (HPV) Testing, Herpes Simplex Virus (HSV) Testing, Syphilis Testing, Trichomonas Testing, Ureaplasma and Mycoplasma Testing), By Location of Testing (Laboratory Testing, Point-of-Care (PoC) Testing) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Molecular Diagnostics for STD Industry Overview

Molecular Testing Is Becoming the Foundation of Modern STI Management

The molecular diagnostics for sexually transmitted diseases industry is evolving rapidly as healthcare systems prioritize early detection, accurate pathogen identification, and improved public health surveillance. Molecular testing technologies have become

increasingly important due to their superior sensitivity, specificity, and ability to identify infections before symptom onset. Rising incidence of sexually transmitted infections, expanding screening initiatives, and growing awareness of asymptomatic transmission are driving adoption of nucleic acid-based diagnostic methods across hospitals, clinical laboratories, sexual health clinics, and public health programs. The industry is moving toward highly automated diagnostic ecosystems capable of delivering reliable results at scale while supporting disease monitoring, treatment guidance, and outbreak control efforts. As healthcare providers seek to improve screening participation and reduce diagnostic delays, molecular diagnostics are becoming central to STI management strategies worldwide.

Multiplex and High-Throughput Platforms Are Enhancing Laboratory Efficiency

A key industry trend is the expansion of multiplex molecular assays capable of simultaneously detecting multiple sexually transmitted pathogens from a single sample. Diagnostic manufacturers are investing in high-throughput systems that improve laboratory productivity while supporting standardized testing workflows. Companies such as Roche and Hologic continue to strengthen the capabilities of their molecular diagnostic platforms, including the cobas® portfolio, to support rapid and automated pathogen detection across a broad range of infectious diseases. These developments align with the growing demand for centralized testing infrastructure capable of processing large sample volumes while maintaining diagnostic accuracy and operational efficiency. Multiplex testing also supports faster clinical decision-making by reducing the need for multiple sequential tests and enabling comprehensive pathogen screening within a single workflow.

Patient-Centric Sample Collection Is Expanding Access to STI Screening

The industry is increasingly focused on removing barriers that prevent individuals from accessing diagnostic services. OraSure Technologies received FDA clearance for the Colli-Pee™•Dx Urine Collection Kit, a self-collection solution designed for at-home or private first-void urine collection for sexually transmitted infection testing. The device incorporates NucleoPrecision™ Technology for DNA and RNA stabilization and is designed for integration with Roche's cobas® molecular testing systems. This development reflects a broader market shift toward patient-centric diagnostics that combine the convenience of home-based sample collection with the analytical performance of centralized laboratory testing. By reducing discomfort, privacy concerns, and logistical obstacles associated with traditional sample collection, the industry aims to increase screening participation, improve disease detection rates, facilitate earlier

treatment intervention, and strengthen public health surveillance efforts for sexually transmitted infections.

Molecular Diagnostics For STD Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Molecular Diagnostics For STD market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Hologic, Inc., Abbott Laboratories, Danaher Corporation (Cepheid), Becton, Dickinson and Company, bioMérieux SA, QIAGEN N.V., Bio-Rad Laboratories, Inc., Seegene Inc., Visby Medical, Inc.. The Molecular Diagnostics For STD market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Molecular Diagnostics For STD industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth Molecular Diagnostics For STD Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Molecular Diagnostics For STD companies

- Porter's Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

- Detailed SWOT Analysis of global and regional Molecular Diagnostics For STD markets

- Competitive analysis including business description, product analysis, and financial profiles

- Key country specific analysis detailing key factors shaping the short-term and long-term outlook

Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Molecular Diagnostics For STD Market Competitive Benchmarking and Company Analysis

Leading companies in Molecular Diagnostics For STD industry include- F. Hoffmann-La Roche Ltd, Hologic, Inc., Abbott Laboratories, Danaher Corporation (Cepheid), Becton, Dickinson and Company, bioMérieux SA, QIAGEN N.V., Bio-Rad Laboratories, Inc., Seegene Inc., Visby Medical, Inc.. The Molecular Diagnostics For STD market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Molecular Diagnostics For STD Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach \$8.2 Trillion in 2034 from \$5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Molecular Diagnostics For STD market remains one of the strongest-performing segments in the country.

The US Molecular Diagnostics For STD Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Molecular Diagnostics For STD market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Molecular Diagnostics For STD industry. On the medical device front, over 7,000 device

manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Molecular Diagnostics For STD markets

Canada's strong Molecular Diagnostics For STD sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Molecular Diagnostics For STD market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Molecular Diagnostics For STD Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Molecular Diagnostics For STD market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Molecular Diagnostics For STD population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Molecular Diagnostics For STD industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Molecular Diagnostics For STD market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Molecular Diagnostics For STD sales through 2034

France Molecular Diagnostics For STD companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country's National Health Insurance spending target (ONDAM) estimates 3.7% growth in the

country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Molecular Diagnostics For STD Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Molecular Diagnostics For STD distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England's plan to give more than 500,000 staff access to new AI tools.

China Molecular Diagnostics For STD Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Molecular Diagnostics For STD market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Molecular Diagnostics For STD industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China's

basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Molecular Diagnostics For STD industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Molecular Diagnostics For STD Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Molecular Diagnostics For STD market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Molecular Diagnostics For STD market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Molecular Diagnostics For STD Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating

investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Molecular Diagnostics For STD Market Segmentation

By Product

Consumables (Reagents and Kits)

Instruments and Services

Software

By Application

Chlamydia Trachomatis / Neisseria Gonorrhoeae (CT/NG) Testing

Human Immunodeficiency Virus (HIV) Testing

Human Papillomavirus (HPV) Testing

Herpes Simplex Virus (HSV) Testing

Syphilis Testing

Trichomonas Testing

Ureaplasma and Mycoplasma Testing

By Location of Testing

Laboratory Testing

Point-of-Care (PoC) Testing

Leading Companies in Molecular Diagnostics For STD Industry (2026)

F. Hoffmann-La Roche Ltd

Hologic, Inc.

Abbott Laboratories

Danaher Corporation (Cepheid)

Becton, Dickinson and Company

bioMérieux SA

QIAGEN N.V.

Bio-Rad Laboratories, Inc.

Seegene Inc.

Visby Medical, Inc.

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia,
Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa,
Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market developments

Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry

Contents

CHAPTER 1- EXECUTIVE SUMMARY

- 1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
- 1.2. Key Industry Highlights, 2026
- 1.3. Premium Market Insights
 - 1.3.1. Potential Molecular Diagnostics For STD Market Types and Applications
 - 1.3.2. Fastest Growing Countries Over the forecast period
- 1.4. Market Scope and Segmentation
 - 1.4.1. Key Market Segments
 - 1.4.2. Key Countries and Regions
 - 1.4.3. Top Companies in the Molecular Diagnostics For STD Industry
- 1.5. Macroeconomic and Demographic Outlook
 - 1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
 - 1.5.2. Population Forecast by Country, 2010- 2040
 - 1.5.3. Inflation Trends in Leading Countries
- 1.6. Impact of Trade Policies, Regulations, and Sustainability
 - 1.6.1. Trade tariffs and localization requirements
 - 1.6.2. ESG and sustainability pressures
 - 1.6.3. Compliance-driven structural changes in the value chain

CHAPTER 2- RESEARCH METHODOLOGY

- 2.1. Report Coverage
- 2.2. Secondary Research
- 2.3. Primary Research
- 2.4. Data Triangulation
- 2.5. Market Modeling and Forecasting

CHAPTER 3- GLOBAL MOLECULAR DIAGNOSTICS FOR STD MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034

- 3.1. An Introduction to Global Molecular Diagnostics For STD Markets in 2026
- 3.2. Global Historic and Forecast Molecular Diagnostics For STD Market Size Outlook, USD Million, 2021- 2034
- 3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
- 3.4. Market Dynamics
 - 3.4.1. Key Molecular Diagnostics For STD Market Driving Forces and Their Impact on

Market Outlook

3.4.2. Short and Long-Term Trends and Insights Shaping the Future

3.4.3. Potential Molecular Diagnostics For STD Market Opportunities for Industry Stakeholders

3.4.4. Potential Challenges across Molecular Diagnostics For STD Value Chain

CHAPTER 4- MOLECULAR DIAGNOSTICS FOR STD MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT

4.1. Porter's Five Forces Analysis

4.1.1. Bargaining Power of Buyers

4.1.2. Bargaining Power of Suppliers

4.1.3. Threat of Substitutes

4.1.4. Threat of New Entrants

4.1.5. Intensity of Competitive Rivalry

4.1.6. Market Attractiveness Analysis by Segment

4.1.7. Market Attractiveness Analysis by Region

4.2. Competitive Landscape

4.2.1 Market Share Analysis of Leading Molecular Diagnostics For STD Companies

4.2.2 Recent Strategic Developments

4.2.3 Mergers, Acquisitions, and Partnerships

4.2.4 Product Launches and Innovation Trends

4.2.5 Key Success Factors

4.3. Value Chain Analysis

4.3.1. Key Value Chain Segments

4.3.2. Dominant players by value-chain stage

4.4. SWOT Analysis

4.4.1. Key Strengths and Opportunities

4.4.2. Major Weaknesses and Threats

4.5 Technology Roadmap

4.6 Regulatory and Reimbursement Landscape

CHAPTER 5- MOLECULAR DIAGNOSTICS FOR STD MARKET OUTLOOK BY SEGMENTS

5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034

5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034

5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product

Consumables (Reagents and Kits)
Instruments and Services
Software
By Application
Chlamydia Trachomatis / Neisseria Gonorrhoeae (CT/NG) Testing
Human Immunodeficiency Virus (HIV) Testing
Human Papillomavirus (HPV) Testing
Herpes Simplex Virus (HSV) Testing
Syphilis Testing
Trichomonas Testing
Ureaplasma and Mycoplasma Testing
By Location of Testing
Laboratory Testing
Point-of-Care (PoC) Testing

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

6.1. Base Case Scenario
 6.1.1. Definitions and Insights
 6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
 6.2.1. Definitions and Insights
 6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
 6.3.1. Definitions and Insights
 6.3.2. Market Size Outlook to 2034

CHAPTER 7- NORTH AMERICA MOLECULAR DIAGNOSTICS FOR STD MARKET SIZE ANALYSIS AND OUTLOOK

7.1. North America Molecular Diagnostics For STD Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Molecular Diagnostics For STD Market Trends and Growth Opportunities to 2034
7.5. North America Molecular Diagnostics For STD Market Size Outlook by Type
7.6. North America Molecular Diagnostics For STD Market Size Outlook by Application
7.7. North America Molecular Diagnostics For STD Market Size Outlook by Country
7.8. United States

- 7.8.1. Key Statistics
- 7.8.2. The US Molecular Diagnostics For STD Market Size Outlook, 2021- 2034
- 7.8.3. Key Market Drivers and Industry Developments in the US Molecular Diagnostics For STD Companies
- 7.9. Canada
 - 7.9.1. Key Statistics
 - 7.9.2. Canada Molecular Diagnostics For STD Market Size Outlook, 2021- 2034
 - 7.9.3. Key Market Drivers and Industry Developments in Canada Molecular Diagnostics For STD Companies
- 7.10. Mexico
 - 7.10.1. Key Statistics
 - 7.10.2. Mexico Molecular Diagnostics For STD Market Size Outlook, 2021- 2034
 - 7.10.3. Key Market Drivers and Industry Developments in Mexico Molecular Diagnostics For STD Companies

CHAPTER 8- EUROPE MOLECULAR DIAGNOSTICS FOR STD MARKET SIZE ANALYSIS AND OUTLOOK

- 8.1. Europe Molecular Diagnostics For STD Market Overview, 2026
- 8.2. Leading Companies Operating in Europe
- 8.3. Key Industry Statistics, 2026
- 8.4. Europe Molecular Diagnostics For STD Market Trends and Growth Opportunities to 2034
- 8.5. Europe Molecular Diagnostics For STD Market Size Outlook by Type
- 8.6. Europe Molecular Diagnostics For STD Market Size Outlook by Application
- 8.7. Europe Molecular Diagnostics For STD Market Size Outlook by Country
- 8.8. Germany
 - 8.8.1. Key Statistics
 - 8.8.2. Germany Molecular Diagnostics For STD Market Size Outlook, 2021- 2034
 - 8.8.3. Key Market Drivers and Industry Developments in Germany Molecular Diagnostics For STD Companies
- 8.9. France
 - 8.9.1. Key Statistics
 - 8.9.2. France Molecular Diagnostics For STD Market Size Outlook, 2021- 2034
 - 8.9.3. Key Market Drivers and Industry Developments in France Molecular Diagnostics For STD Companies
- 8.10. United Kingdom
 - 8.10.1. Key Statistics
 - 8.10.2. United Kingdom Molecular Diagnostics For STD Market Size Outlook, 2021-

2034

8.10.3. Key Market Drivers and Industry Developments in the UK Molecular Diagnostics For STD Companies

8.11. Spain

8.11.1. Key Statistics

8.11.2. Spain Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

8.11.3. Key Market Drivers and Industry Developments in Spain Molecular Diagnostics For STD Companies

8.12. Italy

8.12.1. Key Statistics

8.12.2. Italy Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

8.12.3. Key Market Drivers and Industry Developments in Italy Molecular Diagnostics For STD Companies

8.13. Rest of Europe

8.13.1. Key Statistics

8.13.2. Rest of Europe Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Molecular Diagnostics For STD Companies

CHAPTER 9- ASIA PACIFIC MOLECULAR DIAGNOSTICS FOR STD MARKET SIZE ANALYSIS AND OUTLOOK

9.1. Asia Pacific Molecular Diagnostics For STD Market Overview, 2026

9.2. Leading Companies Operating in Asia Pacific

9.3. Key Industry Statistics, 2026

9.4. Asia Pacific Molecular Diagnostics For STD Market Trends and Growth Opportunities to 2034

9.5. Asia Pacific Molecular Diagnostics For STD Market Size Outlook by Type

9.6. Asia Pacific Molecular Diagnostics For STD Market Size Outlook by Application

9.7. Asia Pacific Molecular Diagnostics For STD Market Size Outlook by Country

9.8. China

9.8.1. Key Statistics

9.8.2. China Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

9.8.3. Key Market Drivers and Industry Developments in China Molecular Diagnostics For STD Companies

9.9. Japan

9.9.1. Key Statistics

9.9.2. Japan Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

9.9.3. Key Market Drivers and Industry Developments in Japan Molecular Diagnostics For STD Companies

9.10. India

9.10.1. Key Statistics

9.10.2. India Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

9.10.3. Key Market Drivers and Industry Developments in India Molecular Diagnostics For STD Companies

9.11. South Korea

9.11.1. Key Statistics

9.11.2. South Korea Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

9.11.3. Key Market Drivers and Industry Developments in South Korea Molecular Diagnostics For STD Companies

9.12. Australia

9.12.1. Key Statistics

9.12.2. Australia Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

9.12.3. Key Market Drivers and Industry Developments in Australia Molecular Diagnostics For STD Companies

9.13. Southeast Asia

9.13.1. Key Statistics

9.13.2. Southeast Asia Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Molecular Diagnostics For STD Companies

CHAPTER 10- SOUTH AND CENTRAL AMERICA MOLECULAR DIAGNOSTICS FOR STD MARKET SIZE ANALYSIS AND OUTLOOK

10.1. South and Central America Molecular Diagnostics For STD Market Overview, 2026

10.2. Leading Companies Operating in South and Central America

10.3. Key Industry Statistics, 2026

10.4. South and Central America Molecular Diagnostics For STD Market Trends and Growth Opportunities to 2034

10.5. South and Central America Molecular Diagnostics For STD Market Size Outlook by Type

10.6. South and Central America Molecular Diagnostics For STD Market Size Outlook by Application

10.7. South and Central America Molecular Diagnostics For STD Market Size Outlook by Country

10.8. Brazil

10.8.1. Key Statistics

10.8.2. Brazil Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

10.8.3. Key Market Drivers and Industry Developments in Brazil Molecular Diagnostics For STD Companies

10.9. Argentina

10.9.1. Key Statistics

10.9.2. Argentina Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

10.9.3. Key Market Drivers and Industry Developments in Argentina Molecular Diagnostics For STD Companies

10.10. Rest of Latin America

10.10.1. Key Statistics

10.10.2. Rest of Latin America Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Molecular Diagnostics For STD Companies

CHAPTER 11- MIDDLE EAST AND AFRICA MOLECULAR DIAGNOSTICS FOR STD MARKET SIZE ANALYSIS AND OUTLOOK

11.1. Middle East and Africa Molecular Diagnostics For STD Market Overview, 2026

11.2. Leading Companies Operating in Middle East and Africa

11.3. Key Industry Statistics, 2026

11.4. Middle East and Africa Molecular Diagnostics For STD Market Trends and Growth Opportunities to 2034

11.5. Middle East and Africa Molecular Diagnostics For STD Market Size Outlook by Type

11.6. Middle East and Africa Molecular Diagnostics For STD Market Size Outlook by Application

11.7. Middle East and Africa Molecular Diagnostics For STD Market Size Outlook by Country

11.8. Saudi Arabia

11.8.1. Key Statistics

11.8.2. Saudi Arabia Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Molecular Diagnostics For STD Companies

11.9. United Arab Emirates

11.9.1. Key Statistics

11.9.2. The UAE Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

11.9.3. Key Market Drivers and Industry Developments in the UAE Molecular
Diagnostics For STD Companies

11.10. Africa

11.10.1. Key Statistics

11.10.2. Africa Molecular Diagnostics For STD Market Size Outlook, 2021- 2034

11.10.3. Key Market Drivers and Industry Developments in Africa Molecular
Diagnostics For STD Companies

CHAPTER 12- COMPANY PROFILES

12.1. Top Companies in Molecular Diagnostics For STD Industry

F. Hoffmann-La Roche Ltd

Hologic, Inc.

Abbott Laboratories

Danaher Corporation (Cepheid)

Becton, Dickinson and Company

bioMérieux SA

QIAGEN N.V.

Bio-Rad Laboratories, Inc.

Seegene Inc.

Visby Medical, Inc.

12.2. Business Description

12.3. SWOT Profiles

12.4. Products and Services

CHAPTER 13- APPENDIX

Glossary of Terms

Research Methodology & Data Sources

Conclusion & Strategic Recommendations

I would like to order

Product name: Molecular Diagnostics For STD Market Size, Share and Growth Outlook 2026: By Product (Consumables (Reagents and Kits), Instruments and Services, Software), By Application, By Location of Testing, Companies to 2034.

Product link: <https://marketpublishers.com/r/M6993DAD57C5EN.html>

Price: US\$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M6993DAD57C5EN.html>